Rin Ogiya
Research Subjects
Research Interests
Rin Ogiya has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Naoki Niikura
Department of Breast Oncology, Tokai University School of Medicine, Isehara, Japan
2 shared publications Yasuaki Sagara
Department of Breast Surgical Oncology, Hakuaikai Medical Cooperation, Sagara Hospital, Kagoshima, Japan
2 shared publications- Asuka Miyamoto
Tokai Univ, Dept Mol Life Sci, Div Basic Med Sci & Mol Med, Sch Med, Isehara, Kanagawa 2591193, Japan
1 shared publication - Banri Tsuda
Department of Breast and Endocrine Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
1 shared publication Hideji Masuoka
Kotoni Breast Clinic, Sapporo, Japan
1 shared publicationHiraku Kumamaru
Department of Healthcare Quality Assessment, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
1 shared publication
Latest Publications
- 20 August 2020
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 184 (2) , 585-596
Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study
Background Breast cancer survival outcomes vary across different ethnic groups. We clarified the differences in clinicopathological and survival characteristics of breast cancer among Japanese, US residents with Japanese origin (USJ), and US residents with other origins (USO). Method Using Surveillance, Epidemiology, and End Results (SEER) 18 dataset and Japanese Breast Cancer Society (JBCS) registry, we included patients first diagnosed with breast cancer between 2004 and 2015. We categorized the patients into three groups based on the database and the recorded ethnicity: Japanese (all those from the JBCS registry), USJ (those from SEER with ethnicity: Japanese), and USO (those from SEER with ethnicity other than Japanese). Excluding patients diagnosed after 2012, stage 0, and 4 patients, we examined the overall survival (OS) and breast cancer-specific survival (BCSS) using the Kaplan–Meier method and Cox proportional hazards models, adjusting for age, sex, cancer stage, and hormone receptor (HR) status. Results We identified 7362 USJ, 701,751 USO, and 503,013 Japanese breast cancer patients. The proportion of HR-positive breast cancer was the highest among USJ (71%). OS was significantly longer among Japanese and USJ than USO (Hazard ratio 0.46; 95% Confidence Interval [CI] 0.45–0.47 for Japanese and 0.66 [95% CI 0.59–0.74] for USJ) after adjusting for baseline covariates. BCSS was also significantly higher in the two groups (HR 0.53 [95% CI 0.51–0.55] for Japanese and 0.53 [95% CI 0.52–0.74] for USJ). Conclusions In stage I–III breast cancer, Japanese and US residents with Japanese origin experienced significantly longer survival than US residents with non-Japanese origins.
- 20 August 2020
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 184 (2) , 585-596
Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study
Background Breast cancer survival outcomes vary across different ethnic groups. We clarified the differences in clinicopathological and survival characteristics of breast cancer among Japanese, US residents with Japanese origin (USJ), and US residents with other origins (USO). Method Using Surveillance, Epidemiology, and End Results (SEER) 18 dataset and Japanese Breast Cancer Society (JBCS) registry, we included patients first diagnosed with breast cancer between 2004 and 2015. We categorized the patients into three groups based on the database and the recorded ethnicity: Japanese (all those from the JBCS registry), USJ (those from SEER with ethnicity: Japanese), and USO (those from SEER with ethnicity other than Japanese). Excluding patients diagnosed after 2012, stage 0, and 4 patients, we examined the overall survival (OS) and breast cancer-specific survival (BCSS) using the Kaplan–Meier method and Cox proportional hazards models, adjusting for age, sex, cancer stage, and hormone receptor (HR) status. Results We identified 7362 USJ, 701,751 USO, and 503,013 Japanese breast cancer patients. The proportion of HR-positive breast cancer was the highest among USJ (71%). OS was significantly longer among Japanese and USJ than USO (Hazard ratio 0.46; 95% Confidence Interval [CI] 0.45–0.47 for Japanese and 0.66 [95% CI 0.59–0.74] for USJ) after adjusting for baseline covariates. BCSS was also significantly higher in the two groups (HR 0.53 [95% CI 0.51–0.55] for Japanese and 0.53 [95% CI 0.52–0.74] for USJ). Conclusions In stage I–III breast cancer, Japanese and US residents with Japanese origin experienced significantly longer survival than US residents with non-Japanese origins.
- 1 June 2019
- Published by Elsevier in Clinical Breast Cancer
- Vol. 19 (3) , 200-207.e1
Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer
- 1 June 2019
- Published by Elsevier in Clinical Breast Cancer
- Vol. 19 (3) , 200-207.e1
Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer
- Open Access
- 4 December 2017
- Published by Springer Nature in Breast Cancer
- Vol. 25 (3) , 284-291
B-cell populations are expanded in breast cancer patients compared with healthy controls
Historically, humoral immunity was considered unimportant in anti-tumor immunity, and the differentiation and anti-tumor activity of B cells in breast cancer are poorly understood. However, it was recently discovered that B cells participate in tumor immunity through both antibody production and immunosuppressive mechanisms. We analyzed the expression of B-cell differentiation markers in detail using fluorescence-activated cell sorting to investigate the relationship between B-cell subsets and breast cancer etiology.
- 4 December 2017
- Published by Springer Nature in Breast Cancer
- Vol. 25 (3) , 284-291
Open AccessB-cell populations are expanded in breast cancer patients compared with healthy controls
Historically, humoral immunity was considered unimportant in anti-tumor immunity, and the differentiation and anti-tumor activity of B cells in breast cancer are poorly understood. However, it was recently discovered that B cells participate in tumor immunity through both antibody production and immunosuppressive mechanisms. We analyzed the expression of B-cell differentiation markers in detail using fluorescence-activated cell sorting to investigate the relationship between B-cell subsets and breast cancer etiology.